NEWS & EVENTS

Noema Pharma to attend and present at BioEquity Europe and UBS Global Healthcare Conference in May 2022

BASEL, Switzerland, May 6, 2022 – Noema Pharma, a Swiss clinical-stage Biotech company targeting debilitating central nervous system (CNS) indications, today announces Luigi Costa, Chief Executive …

Noema Pharma appoints Michael Gutch as Chief Financial Officer

BASEL, Switzerland, February 22, 2022 – Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of …

Noema Pharma announces first patient dosed in Phase 2b LibraTN study of mGluR5 inhibitor NOE-101 in trigeminal neuralgia

Study evaluating the efficacy of NOE-101 for management of pain associated with trigeminal neuralgia BASEL, Switzerland, February 22, 2022 – Noema Pharma, a Swiss-based clinical …

Noema Pharma announces publication of “Noema, Basimglurant and a New Clinical Trial for Seizures in TSC” podcast on TSC Alliance website

BASEL, Switzerland, February 22, 2022 – Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces that the TSC …

Noema Pharma announces FDA Investigational New Drug authorization for Phase 2b LibraTN study of mGluR5 inhibitor NOE-101 in trigeminal neuralgia

Study to evaluate efficacy of NOE-101 for management of pain associated with trigeminal neuralgia BASEL, Switzerland, February 14, 2022 – Noema Pharma, a Swiss-based clinical …

Trigeminal Neuralgia – You are not alone, Hosted by Noema Pharma

BASEL, Switzerland, February 8, 2022 – Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announced that it will …

Noema Pharma Hosting Key Opinion Leader Webinar on Stuttering

BASEL, Switzerland, December 8, 2021 – Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announced that it will …

Noema Pharma expands its Board of Directors with the appointments of Catherine Moukheibir and Ilise Lombardo

BASEL, Switzerland, November 9, 2021 – Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of …

Noema Pharma appoints Jeffrey Jonas as Independent Chairman of the Board of Directors

BASEL, Switzerland, October 4, 2021 –Noema Pharma AG, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of …

Noema Pharma to attend Swiss Biotech Day and the UBS Biotech Private Company Symposium in September 2021

BASEL, Switzerland, September 2, 2021 – Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces it will attend …

Noema Pharma initiates Phase 2a Allevia study of PDE10A inhibitor NOE-105 in Tourette Syndrome

First Noema clinical trial, with asset in-licensed from Roche with strong clinical safety package Noema advancing potentially life-changing therapeutics for patients without satisfactory treatments Basel, …

Noema Pharma to Host a Key Opinion Leader Webinar on Seizures in Tuberous Sclerosis Complex

BASEL, Switzerland, July 7, 2021, Basel, Switzerland – Noema Pharma (‘Noema”) AG, a Swiss clinical-stage company targeting orphan neurological disorders, will host a key opinion …

Noema Pharma to Attend Investor Conferences in June and July 2021

BASEL, Switzerland, May 31, 2021, Basel, Switzerland – Noema Pharma (‘Noema”) AG, a Swiss clinical-stage company targeting orphan neurological disorders, today announces it will attend …